利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.017 秒)

    Use of modulators of CCR5 in the treatment of cancer and cancer metastasis
    2.
    发明授权
    Use of modulators of CCR5 in the treatment of cancer and cancer metastasis 有权

    公开(公告)号：US11633397B2

    公开(公告)日：2023-04-25

    申请号：US16363981

    申请日：2019-03-25

    申请人： Richard G. Pestell

    发明人： Richard G. Pestell

    IPC分类号： A61K31/506 ,  G01N33/50 ,  A61K31/46 ,  G01N33/574 ,  A61K31/4184 ,  A61K31/4375 ,  C12Q1/6886

    摘要： This disclosure is directed, in part, to a method of determining whether a subject having cancer is at risk for developing metastasis of the cancer. In one embodiment, the method comprises (a) obtaining a biological sample from the subject having cancer; (b) determining CCR5 expression level and/or expression level of at least one of CCR5 ligands in the biological sample; and (c) if the expression level of CCR5 and/or of at least one of CCR5 ligands determined in step (b) is increased compared to CCR5 expression level and/or expression level of at least one of CCR5 ligands in a control sample, then the subject is identified as likely at risk for developing metastasis of the cancer.

    USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS
    3.
    发明申请
    USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS 审中-公开

    公开(公告)号：US20190314371A1

    公开(公告)日：2019-10-17

    申请号：US16363981

    申请日：2019-03-25

    申请人： Richard G. Pestell

    发明人： Richard G. Pestell

    IPC分类号： A61K31/506 ,  G01N33/50 ,  A61K31/46 ,  C12Q1/6886 ,  G01N33/574 ,  A61K31/4375 ,  A61K31/4184

    摘要： This disclosure is directed, in part, to a method of determining whether a subject having cancer is at risk for developing metastasis of the cancer. In one embodiment, the method comprises (a) obtaining a biological sample from the subject having cancer; (b) determining CCR5 expression level and/or expression level of at least one of CCR5 ligands in the biological sample; and (c) if the expression level of CCR5 and/or of at least one of CCR5 ligands determined in step (b) is increased compared to CCR5 expression level and/or expression level of at least one of CCR5 ligands in a control sample, then the subject is identified as likely at risk for developing metastasis of the cancer.

    Use of modulators of CCR5 in the treatment of Cancer and cancer metastasis
    4.
    发明申请
    Use of modulators of CCR5 in the treatment of Cancer and cancer metastasis 有权
    使用CCR5调节剂治疗癌症和癌症转移

    公开(公告)号：US20130303512A1

    公开(公告)日：2013-11-14

    申请号：US13893791

    申请日：2013-05-14

    申请人： Richard G. PESTELL

    发明人： Richard G. PESTELL

    IPC分类号： G01N33/50 ,  A61K31/506 ,  A61K31/46

    CPC分类号： A61K31/506 ,  A61K31/4184 ,  A61K31/4375 ,  A61K31/46 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/5091 ,  G01N33/57415 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2333/705 ,  G01N2333/7158 ,  G01N2800/56

    摘要： This disclosure is directed, in part, to a method of determining whether a subject having cancer is at risk for developing metastasis of the cancer. In one embodiment, the method comprises (a) obtaining a biological sample from the subject having cancer; (b) determining CCR5 expression level and/or expression level of at least one of CCR5 ligands in the biological sample; and (c) if the expression level of CCR5 and/or of at least one of CCR5 ligands determined in step (b) is increased compared to CCR5 expression level and/or expression level of at least one of CCR5 ligands in a control sample, then the subject is identified as likely at risk for developing metastasis of the cancer.

    摘要翻译： 本公开部分地涉及确定患有癌症的受试者是否存在发展为癌症转移的风险的方法。 在一个实施方案中，该方法包括（a）从具有癌症的受试者获得生物样品; （b）确定生物样品中CCR5配体的至少一种的CCR5表达水平和/或表达水平; 和（c）如果在对照样品中与CCR5配体的CCR5表达水平和/或表达水平相比，步骤（b）中确定的CCR5和/或至少一种CCR5配体的表达水平升高， 那么该受试者被鉴定为可能发生癌症转移的风险。

    Caged ligands and uses thereof
    7.
    发明授权
    Caged ligands and uses thereof 有权
    笼式配体及其用途

    公开(公告)号：US08076318B2

    公开(公告)日：2011-12-13

    申请号：US10532009

    申请日：2003-10-22

    申请人： David S. Lawrence ,  Richard G. Pestell ,  Christopher Albanese

    发明人： David S. Lawrence ,  Richard G. Pestell ,  Christopher Albanese

    IPC分类号： A61K31/56 ,  A01N45/00

    CPC分类号： B82Y5/00 ,  A61K31/56 ,  A61K41/0042 ,  A61K47/554 ,  A61K47/6949 ,  A61K48/005 ,  A61K48/0058 ,  C12N15/67

    摘要： Provided are caged compounds comprising a ligand that specifically reacts with a receptor not naturally present in mammals. The cage is released from the ligand upon illumination of the compound with light. Also provided are cells transfected with a gene of interest and a gene encoding a receptor, the gene of interest operably linked to a genetic element capable of being induced by the receptor when bound to a ligand, and the receptor not naturally present in the species of the cell. The cells also comprise a caged ligand of the receptor. Additionally provided are methods of inducing a gene of interest in the above cells. Also provided are methods of repressing a gene of interest in a cell using caged ligands of receptors. Methods are additionally provided for inducing elimination of a target sequence in a cell of a species, using a caged ligand and a recombinase.

    摘要翻译： 提供了包含与哺乳动物中天然存在的受体特异性反应的配体的笼养化合物。 在用光照射化合物时，笼从配体释放出来。 还提供了用感兴趣的基因转染的细胞和编码受体的基因，该靶基因可操作地连接到当与配体结合时能够被受体诱导的遗传元件，以及不天然存在于该物种中的受体 细胞。 细胞还包含受体的笼状配体。 另外提供了在上述细胞中诱导目的基因的方法。 还提供了使用笼式受体配体抑制细胞中目的基因的方法。 另外提供了使用笼式配体和重组酶诱导物种细胞中靶序列的消除的方法。

    PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF
    8.
    发明公开
    PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF 审中-公开

    公开(公告)号：US20240224960A1

    公开(公告)日：2024-07-11

    申请号：US17167578

    申请日：2021-02-04

    申请人： Richard G. Pestell

    发明人： Richard G. Pestell

    IPC分类号： A01K67/0275 ,  A61K31/46 ,  A61K31/506 ,  C12N5/09 ,  C12Q1/6886 ,  G01N33/574

    CPC分类号： A01K67/0275 ,  A61K31/46 ,  A61K31/506 ,  C12N5/0693 ,  C12Q1/6886 ,  G01N33/574

    摘要： The present disclosure, in part, is directed to a mammalian prostate cancer cell line comprising at least one or a set of primary mammalian epithelial cells which have been infected with a retroviral vector carrying an oncogene selected from the group consisting of c-Myc, Ha-Ras, NeuT, c-Src and combinations thereof and in which said gene is expressed. Applications of the prostate cell lines, including immune competent animal models of prostate cancer, a method for the in vitro production of immortalized primary mammalian epithelial cells, a method of determining whether a human subject having prostate cancer is suffering from or at risk for developing metastasis, a method of preventing cancer or inhibiting metastasis of cancer susceptible to treatment in a subject at risk for developing cancer or metastasis of cancer, and method of identifying a candidate compound that selectively interferes with proliferation or viability of a cancer cell that has elevated levels of CCR5 and/or of at least one of its ligands.

    Prostate cancer cell lines, gene signatures and uses thereof
    9.
    发明授权
    Prostate cancer cell lines, gene signatures and uses thereof 有权

    公开(公告)号：US10952415B2

    公开(公告)日：2021-03-23

    申请号：US14003384

    申请日：2012-03-09

    申请人： Richard G. Pestell

    发明人： Richard G. Pestell

    IPC分类号： A61K31/46 ,  A01K67/027 ,  C12N5/09 ,  A61K31/506 ,  C12Q1/6886 ,  G01N33/574

    摘要： The present disclosure, in part, is directed to a mammalian prostate cancer cell line comprising at least one or a set of primary mammalian epithelial cells which have been infected with a retroviral vector carrying an oncogene selected from the group consisting of c-Myc, Ha-Ras, NeuT, c-Src and combinations thereof and in which said gene is expressed. Applications of the pro-state cell lines, including immune competent animal models of prostate cancer, a method for the in vitro production of immortalized primary mammalian epithelial cells, a method of determining whether a human subject having prostate cancer is suffering from or at risk for developing metastasis, a method of preventing cancer or inhibiting metastasis of cancer susceptible to treatment in a subject at risk for developing cancer or metastasis of cancer, and method of identifying a candidate compound that selectively interferes with proliferation or viability of a cancer cell that has elevated levels of CCR5 and/or of at least one of its ligands.

    Use of modulators of CCR5 in the treatment of cancer and cancer metastasis
    10.
    发明授权
    Use of modulators of CCR5 in the treatment of cancer and cancer metastasis 有权
    使用CCR5调节剂治疗癌症和癌症转移

    公开(公告)号：US09453836B2

    公开(公告)日：2016-09-27

    申请号：US13893791

    申请日：2013-05-14

    申请人： Richard G. Pestell

    发明人： Richard G. Pestell

    IPC分类号： A61K31/506 ,  A61K31/46 ,  G01N33/50 ,  G01N33/574

    CPC分类号： A61K31/506 ,  A61K31/4184 ,  A61K31/4375 ,  A61K31/46 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/5091 ,  G01N33/57415 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2333/705 ,  G01N2333/7158 ,  G01N2800/56

    摘要： This disclosure is directed, in part, to a method of determining whether a subject having cancer is at risk for developing metastasis of the cancer. In one embodiment, the method comprises (a) obtaining a biological sample from the subject having cancer; (b) determining CCR5 expression level and/or expression level of at least one of CCR5 ligands in the biological sample; and (c) if the expression level of CCR5 and/or of at least one of CCR5 ligands determined in step (b) is increased compared to CCR5 expression level and/or expression level of at least one of CCR5 ligands in a control sample, then the subject is identified as likely at risk for developing metastasis of the cancer.

    摘要翻译： 本公开部分地涉及确定患有癌症的受试者是否存在发展为癌症转移的风险的方法。 在一个实施方案中，该方法包括（a）从具有癌症的受试者获得生物样品; （b）确定生物样品中CCR5配体的至少一种的CCR5表达水平和/或表达水平; 和（c）如果在对照样品中与CCR5配体的CCR5表达水平和/或表达水平相比，步骤（b）中确定的CCR5和/或至少一种CCR5配体的表达水平升高， 那么该受试者被鉴定为可能发生癌症转移的风险。